Lipid Nanoparticles Global Market Report 2024

The lipid nanoparticles market size has grown rapidly in recent years. It will grow from $0.89 billion in 2023 to $1.04 billion in 2024 at a compound annual growth rate (CAGR) of 16.9%. The growth observed in the historic period can be attributed to several key factors. These include the heightened focus on the development of LNP-based drugs, significant investments in research infrastructure, and the steady increase in healthcare expenditures. These factors collectively contributed to the expansion of the lipid nanoparticle market, driving innovation and advancements in drug delivery technologies.

The lipid nanoparticles market size is expected to see rapid growth in the next few years. It will grow to $1.94 billion in 2028 at a compound annual growth rate (CAGR) of 17%. The anticipated growth in the forecast period can be attributed to several key drivers. These include the rising prevalence of chronic diseases, a growing demand for RNA-based therapeutics, increasing interest in advanced gene delivery systems, the expanding focus on personalized medicine, and rising investments in research and development initiatives. These factors are expected to fuel the growth of the lipid nanoparticle market, driving innovation and the development of new therapeutic solutions. Key trends expected in the forecast period encompass advancements in drug delivery technologies, the emergence of innovative drug delivery systems, and the integration of artificial intelligence in LNP development processes. These trends are poised to enhance the efficiency and effectiveness of lipid nanoparticle-based therapies, further propelling market growth and expanding therapeutic possibilities.

The escalating prevalence of chronic diseases is serving as a catalyst for the growth of the lipid nanoparticles market. Chronic diseases, characterized by enduring conditions lasting over three months, encompass ailments like diabetes, hypertension, and various other health disorders. Contributing factors to the rising rates of chronic diseases include poor health behaviors, an aging population, lifestyle choices, tobacco use, inadequate nutrition, physical inactivity, and excessive alcohol consumption. Lipid nanoparticles present a promising avenue in chronic disease management by enhancing the efficacy of mRNA therapeutics and vaccines. LNPs revolutionize the treatment landscape for a spectrum of chronic diseases, offering prospects for more effective management strategies and potentially improved patient outcomes. For instance, data published by the International Diabetes Federation in 2021 revealed that 537 million adults aged 20 to 79 were living with diabetes, with projections indicating an increase to 643 million by 2030 and 783 million by 2045, underscoring the pivotal role of LNPs in addressing the rising burden of chronic diseases.

Key players in the lipid nanoparticles market are spearheading innovations in circular RNA (circRNA) and lipid nanoparticle (LNP) formulations to gain a competitive advantage. The advancement of circular RNA (circRNA) and lipid nanoparticle (LNP) formulations expands the repertoire of RNA formats, including circRNA, a single-stranded RNA characterized by a covalently closed loop structure. For instance, in September 2023, GenScript Biotech, a prominent US-based life sciences company, augmented its reagent services to encompass circular RNA (circRNA) and lipid nanoparticles (LNP) formulation. These enhanced services align with GenScript's commitment to providing protein replacement therapies, gene and cell therapy solutions, and are readily available as part of the company's contract-manufactured reagent services. CircRNA offers several advantages over traditional linear RNA, including heightened stability, slower degradation, and the potential to achieve therapeutic protein levels at lower dosages.

In February 2022, Merck & Co., Inc., a leading US-based pharmaceutical company, completed the acquisition of Exelead for $780 million in cash. This strategic acquisition bolsters Merck's Life Science division by enabling the provision of comprehensive contract development and manufacturing organization (CDMO) services across the mRNA value chain. Exelead, a reputable US-based biopharmaceutical CDMO, specializes in the production of PEGylated products and complex injectable formulations, including lipid nanoparticle (LNP) based drug delivery technology, augmenting Merck's capabilities in advancing innovative therapies for chronic diseases.

Major companies operating in the lipid nanoparticles market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Abbott Laboratories, Amgen Inc, The Merck Group, Evonik Industries AG, BioNTech SE, Moderna Inc., Sanofi SA, Solid Biosciences Inc., AstraZeneca PLC, NOF Corporation, Alnylam Pharmaceuticals Inc., Nanomerics Ltd., CordenPharma International, Nippon Fine Chemical, Helix Biotech Inc., Dicerna Pharmaceuticals, Gattefossé SAS, Arbutus Biopharma, Avanti Polar Lipids, IOI Oleo GmbH, Evox Therapeutics Ltd.

North America was the largest region in the lipid nanoparticles market in 2023. The regions covered in the lipid nanoparticles market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lipid nanoparticles market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Lipid nanoparticles are a class of nanoparticles primarily composed of lipids, essential fatty substances integral to cell membranes. These nanoparticles typically consist of a lipid bilayer or solid lipid matrix, characterized by their small size, typically ranging from 10 to 1000 nanometers in diameter.

The primary types of lipid nanoparticles include nanostructured lipid carriers (NLCs), solid lipid nanoparticles (SLNs), and other variations. Nanostructured lipid carriers (NLCs) are small structures composed of fats capable of encapsulating drugs or nutrients. They find applications in various fields including research and therapeutics and are utilized by diverse end-users such as pharmaceutical and biotechnology companies, academic and research institutions, and others.

The lipid nanoparticles market research report is one of a series of new reports that provides lipid nanoparticles market statistics, including lipid nanoparticles industry global market size, regional shares, competitors with a lipid nanoparticles market share, detailed lipid nanoparticles market segments, market trends, and opportunities, and any further data you may need to thrive in the lipid nanoparticles industry. This lipid nanoparticles market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lipid nanoparticles market consists of sales of solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and lipid-based nanoparticles (LBNPs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.